Objective: To confirm the results of an earlier study showing premenopausal equol excretors to have hormone profiles associated with reduced breast cancer risk, and to investigate whether equol excretion status and plasma hormone concentrations can be influenced by consumption of probiotics. Design: A randomized, single-blinded, placebo-controlled, parallel-arm trial. Subjects: In all, 34 of the initially enrolled 37 subjects completed all requirements. Intervention: All subjects were followed for two full menstrual cycles and the first seven days of a third cycle. During menstrual cycle 1, plasma concentrations of estradiol (E 2 ), estrone (E 1 ), estrone-sulfate (E 1 -S), testosterone (T), androstenedione (A), dehydroepiandrosterone-sulfate (DHEA-S), and sex-hormone-binding globulin (SHBG) were measured on cycle day 2, 3, or 4, and urinary equol measured on day 7 after a 4-day soy challenge. Subjects then received either probiotic capsules (containing Lactobacillus acidophilus and Bifidobacterium longum) or placebo capsules through day 7 of menstrual cycle 3, at which time both the plasma hormone concentrations and the post-soy challenge urinary equol measurements were repeated. Results: During menstrual cycle 1, equol excretors and non-excretors were not significantly different with respect to subject characteristics, diet, or hormone concentrations. Significant inverse correlations were found between E 2 and body mass index (BMI) (P ¼ 0.02), SHBG and BMI (P ¼ 0.01), DHEA-S and dietary fiber (P ¼ 0.04), and A and protein:carbohydrate ratio (P ¼ 0.02). Probiotic consumption failed to significantly alter equol excretor status or hormone concentrations during menstrual cycle 3, although there were trends towards decreased concentrations of T (P ¼ 0.14) and SHBG (P ¼ 0.10) in the probiotic group. Conclusions: We were unable to verify a previously reported finding of premenopausal equol excretors having plasma hormone concentrations different from those of nonexcretors. Furthermore, a 2-month intervention with probiotic capsules did not significantly alter equol excretion or plasma hormone concentrations.
Introduction
Several lines of evidence suggest that consumption of isoflavones, phytoestrogens abundant in soy foods, may decrease the risk of breast cancer, possibly on the basis of associated changes in sex steroid action. Such evidence includes case-control studies showing that increased soy intake is associated with reduced breast cancer risk (Lee et al, 1991; Wu et al, 1996; Zheng et al, 1999; Dai et al, 2002) . In particular, the isoflavone-metabolite equol has been of interest, and in a case-control study of women consuming a Western diet, those in the highest quartile of urinary equol excretion had an adjusted odds ratio of 0.27 (95% confidence interval 0.10-0.69) compared to those in the lowest quartile of excretion (Ingram et al, 1997) .
Equol itself is not present in soy foods, but is produced by bacterial metabolism of the isoflavone daidzein. Interestingly, however, only about 30-40% of humans excrete more than trace amounts of equol, regardless of isoflavone intake (Cassidy et al, 1994; Hutchins et al, 1995; Kelly et al, 1995; Lampe et al, 1998; Duncan et al, 2000; Rowland et al, 2000) . Furthermore, in a soy-feeding study in premenopausal women, equol excretors had lower concentrations of sex steroids compared to nonexcretors, regardless of isoflavone dose (Duncan et al, 2000) . These results suggest that the association of equol excretion and decreased breast cancer risk may largely reflect the tendency of equol excretors to have more favorable hormonal profiles from the standpoint of breast cancer risk, as opposed to merely reflecting increased isoflavone intake. If this were the case, equol may be a marker for the presence of colonic bacterial enzymatic activity that both allows for equol to be produced as well as for a favorable sex steroid concentration profile, presumably on the basis of changes in the enterohepatic circulation of steroids.
Owing to the potential biological importance of equol, researchers have investigated whether equol production status can be altered. In fact, it is known that certain dietary changes can alter the bacterial profile of the intestine (Rao, 1995) and may also affect isoflavone metabolism. Two reported attempts have been made to increase equol excretion through dietary means. Lu et al (1996) reportedly increased equol excretion in six premenopausal women given soy milk for 1 month, while Lampe et al (2001) were not able to change equol-excretor status in premenopausal women after giving soy protein or wheat bran for 1 month.
Effects of intestinal bacteria on enterohepatic circulation of steroid hormones may also be relevant to cancer prevention. Lactobacilli and bifidobacteria, two predominant families of intestinal flora (Gibson et al, 1995) , have low b-glucuronidase activity (Hawksworth et al, 1971) , and may reduce enterohepatic circulation of plasma hormones by decreasing hydrolysis of glucuronide-conjugated hormones in the intestine (Rowland et al, 1999) . Furthermore, consumption of lactobacilli and bifidobacteria has been shown to significantly increase b-glucosidase activity in humans (Marteau et al, 1990) , an activity necessary to convert the isoflavone glycoside to an aglycone, and specific strains of bifidobacteria have been shown to increase equol synthesis in vitro (Tsangalis et al, 2003) .
We hypothesized that the ability to convert daidzein to equol is characteristic of bacteria that also reduce enterohepatic circulation of reproductive hormones and may explain the inverse association between equol excretion and breast cancer risk. The objectives of this study were to verify the cancer-preventive reproductive hormone profiles of premenopausal equol excretors and to determine whether consumption of bacteria with low b-glucuronidase activity would increase production of equol and reduce plasma concentrations of reproductive hormones.
Materials and methods

Subjects
Premenopausal women, 18-36 y old, were selected from the Minneapolis/St. Paul metropolitan area after a telephone screening and a detailed self-administered questionnaire. Exclusionary criteria included BMI o18 or 430 kg/m 2 , menstrual cycles o24 or 432 days, antibiotic or exogenous hormone use within the last 3 months, probiotic supplement use within the last 30 days, alcohol consumption greater than seven drinks/week, chronic health problems, regular medication use including aspirin, weight change of more than 10 pounds within the previous year or more than five pounds within the previous 2 months, soy allergy, current pregnancy or lactation. Of the women evaluated for baseline analysis, 72% were Caucasian, 6% were African American, 10% were Asian, 6% were Hispanic, and 6% from South America were multi-racial. In all, 34 subjects completed the entire study.
Experimental design
The University of Minnesota Institutional Review Board, Human Subjects Committee, approved the study protocol. Two-thirds of the subjects were randomized to receive probiotic and one-third randomized to receive placebo capsules for approximately 2 months (5777 days) in a single-blinded, parallel-arm design. Subjects remained freeliving and supplemented their normal diets with a 4-day soy challenge on days 4-7 of menstrual cycles one and three. Beginning on day 8 of menstrual cycle one, all subjects consumed probiotic or placebo capsules daily through day 7 of menstrual cycle three.
Experimental diet
Subjects consumed their habitual diets, but were provided with detailed dietary instructions to minimize the consumption of phytoestrogens and fermented foods. Subjects were also instructed to consume three placebo or probioticcontaining capsules daily on an empty stomach. Each probiotic capsule contained a total of 10 9 colony-forming units 
Study procedures
Body weight was obtained in a hospital gown and fasting blood was drawn in heparinized tubes on days 2, 3 or 4 of menstrual cycles one and three. Plasma was separated, ascorbic acid and sodium azide were added to a final concentration of 0.1%, and aliquots were frozen at À701C until analysis.
Urine collections (24 h) were started in the morning of day 7 of menstrual cycles one and three, the final day of each 4-day soy challenge. Urine was collected in plastic containers containing 1 g of ascorbic acid per liter and separated into aliquots after the addition of sodium azide to a final concentration of 0.1%. Aliquots were frozen at -201C until analysis. Urinary creatinine was measured to assess the completeness of collection.
Dietary data were collected at baseline and following the 2-month intervention using the Healthy Habits and History Questionnaire (Block et al, 1986) , a food frequency questionnaire containing 63 items, which incorporates the portion size of foods consumed into the final analysis. The questionnaire included consumption of food items such as yogurt and milk substitute, which would help assess subject compliance to dietary restrictions.
Analytical methods
All plasma samples were analyzed for estradiol (E 2 ), estrone (E 1 ), estrone-sulfate (E 1 -S), testosterone (T), androstenedione (A), dehydroepiandrosterone-sulfate (DHEA-S), and sex hormone binding globulin (SHBG). All samples were analyzed for each hormone in one batch by double antibody RIA, using 125 I-labeled hormone (Diagnostics Systems Laboratories, Inc., Webster, TX, USA). Intra-assay variabilities were o4% for all analytes.
Urine was analyzed for equol by competitive time-resolved fluoroimmunoassay as previously described (Brouwers et al, 2003) . Intra-assay coefficients of variation were between 3.4 and 6.9%, and inter-assay coefficients of variation were between 7.4 and 7.7%, at three different concentration levels. The values were corrected by a formula to correspond to values obtained by reference gas chromatographic-mass spectrometric methods and mean recoveries were 94.3% (Brouwers et al, 2003) .
Dietary information was analyzed with DietSys Software version 4.0 (National Cancer Institute, 1997). Diets were evaluated for energy, dietary fiber, macronutrient, and micronutrient content.
Statistical analysis
Although there are no established levels of equol excretion that separate equol excretors from nonexcretors, subjects fell into two distinct categories. Equol excretors excreted greater than 900 nmol per 24 h and nonexcretors excreted less than 400 nmol per 24 h. No subjects excreted between 400 and 900 nmol per 24 h.
Statistical analysis was performed using the Statistical Analysis System (SAS Institute, Inc., Cary, NC, USA) version 8.2. Comparisons of baseline anthropometric measures, diet, and hormones between placebo and control groups and between equol excretors and nonexcretors were made using two-sample t-tests. Within-subject comparisons of baseline and end-of-intervention hormone, diet, and equol excretion were made using paired t-tests. Spearman correlation coefficients, r, were calculated to assess the relationships among baseline BMI, diet, and hormones. Data are presented as mean7standard deviation (s.d.). Equol and DHEA-S measurements were log transformed for statistical analysis and are presented as geometric mean (95% confidence interval). P-values were considered significant at less than 0.05.
Results
Of the 37 women who started the study, 34 completed all study requirements. Three subjects dropped out during the course of the study, but provided baseline plasma and urine samples as well as dietary data. One subject had a 20-day menstrual cycle during the course of the study and was removed from all analyses. Therefore, 36 women were included in baseline statistics and correlations and 33 were included in evaluation of the dietary intervention.
Subject characteristics, baseline dietary data, and baseline plasma hormones are shown in Table 1 . There were no significant differences in age, body weight, body mass index (BMI), menstrual cycle length, or intake of total energy, protein, carbohydrate, fat, fiber or micronutrients between the probiotic and placebo groups at baseline. There were also no significant differences in plasma hormones between the probiotic and placebo groups at baseline. At baseline, significant inverse correlations were found between E 2 and BMI (r ¼ À0.39, P ¼ 0.02), SHBG and BMI (r ¼ À0.41 P ¼ 0.01), DHEA-S and dietary fiber (r ¼ À0.34, P ¼ 0.04), and between A and protein:carbohydrate ratio (r ¼ À0.40, P ¼ 0.02). No other significant associations were found between baseline BMI or diet and plasma hormone concentrations; however, A tended to decrease with increasing BMI (r ¼ À0.27 P ¼ 0.11) and T tended to decrease with increasing protein:carbohydrate ratio (r ¼ À0.25, P ¼ 0.14).
There were no significant changes in body weight or intake of total energy, carbohydrate, fat, fiber or micronutrients (calcium, phosphorous, iron, sodium, potassium, vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin C, fiber, folate, vitamin E, zinc, vitamin B6, and magnesium) in either group during the intervention (Table 2 , micronutrient data not shown). However, the probiotic group had a significant drop in protein intake (P ¼ 0.006).
Plasma reproductive hormone data are presented in Table 3 . When comparing baseline to end-of-intervention values within probiotic or placebo groups, no significant changes occurred in any of the hormones measured, although there was a trend toward decreased SHBG in the probiotic group (P ¼ 0.10). There were also no significant differences in pre-post hormone changes between the two groups although the probiotic group showed a tendency toward decreased T relative to the placebo group (P ¼ 0.14).
Baseline subject characteristics, dietary intake data, and plasma hormone concentrations of equol excretors and nonexcretors are shown in Table 4 . Of the 36 women included in the analysis at baseline, 13 (36%) were equol excretors. There were no significant differences in age, body weight, BMI, cycle length, or consumption of energy, macronutrients, micronutrients or dietary fiber between equol excretors and nonexcretors. There were also no significant differences between these two groups with respect to E 2 , E 1 , E 1 -S, T, A, DHEA-S or SHBG, although the excretors showed a nonsignificant trend toward lower E 1 , E 1 -S and T, and higher SHBG.
Excretion of equol (expressed as nmol/24 h) did not change significantly in excretors or nonexcretors following the 2-month intervention in either the treatment or placebo group (Table 5) . Results were the same when equol excretion was expressed per mg of urinary creatinine. Several individuals increased excretion during the study although increases in those receiving probiotic capsules were similar in magnitude to those receiving placebo. All values are mean7s.d. except DHEA-S and equol, which are shown as geometric mean (95% CI). Within the probiotic group, n ¼ 7 excretors and n ¼ 15 nonexcretors; within the placebo group, n ¼ 6 excretors and n ¼ 5 nonexcretors.
Discussion
Although we found a tendency toward lower E 1 , E 1 -S and T, and higher SHBG concentrations in premenopausal equol excretors, none of these differences were statistically significant. Thus, previously reported hormone differences between premenopausal equol excretors and nonexcretors (Duncan et al, 2000) were not confirmed in this study. However, a major difference between the two studies should be noted. In the Duncan et al study, subjects consumed soy protein isolate providing between 10 and 128 mg isoflavones/day. Although the researchers intended the lowest dose to be a control against which the higher doses could be compared, their lowest isoflavone dose (10 mg/day) approaches current estimates of typical intake in Japan. As suggested by these researchers, it is possible that the equol synthesized from this low isoflavone dose may have been sufficient to alter plasma hormones in equol excretors. In our study, subjects were required to abstain from all soy products and were exposed to negligible quantities of isoflavones. Taken together, these two studies suggest that equol excretors show lowered hormone concentrations only when exposed to small quantities of isoflavones (10 mg/day).
On the other hand, a recent report showed no hormonal effects in premenopausal women consuming isoflavone supplements (Maskarinec et al, 2002) , although, in this latter study, the number of equol excretors was unusually low, suggesting that their method of equol detection was not very sensitive and many of the equol excretors may have gone undetected. It is also possible that isoflavone effects differ when provided as purified supplements, as opposed to those in soy protein isolate, as in our study. We also found no significant differences between equol excretors and nonexcretors with respect to dietary intake. Although equol excretion has been positively correlated with total fat and meat intake and fat-to-fiber ratio (Adlercreutz et al, 1991) , processed and high-fat meat (Lampe et al, 1999) and carbohydrate, fiber, plant protein, and percent of energy as carbohydrate (Lampe et al, 1998; Rowland et al, 2000) , our findings agree with other research showing no unique dietary patterns in equol excretors (Hutchins et al, 1995; Duncan et al, 2000; Lampe et al, 2001) . Our results showing no differences in age, body weight, BMI, and cycle length between excretors and nonexcretors also agree with previously published results (Duncan et al, 2000; Lampe et al, 2001) . However, these results must be interpreted with caution, as they are limited by small sample sizes, homogenous populations, and insensitive dietary assessment tools.
Consumption of probiotic capsules did not alter equol excretor status in this study even though the dose of probiotic provided was similar in dose to other studies in which the enzyme activity of the intestinal flora was shown to be altered (Goldin and Gorbach, 1984; Benno and Mitsuoka, 1992) . It is possible that probiotic consumption altered the intestinal environment but not enough to significantly increase equol production. This lack of effect of isoflavone hydrolysis on increasing isoflavone-metabolite excretion is consistent with another study in which consumption of a beverage containing isoflavone aglycones did not increase urinary equol excretion in comparison with consumption of the same beverage containing conjugated isoflavones (Richelle et al, 2002) .
Only one report exists of nonexcretors gaining the ability to excrete measurable amounts of equol following a 1-month soy intervention (Lu et al, 1996) , although this study was limited by initial labeling of equol excretors and Values are geometric mean (95% CI). Within the probiotic group, n ¼ 7 excretors and n ¼ 15 nonexcretors; within the placebo group, n ¼ 6 excretors and n ¼ 5 nonexcretors.
nonexcretors following only one dose of soymilk. A more recent study using a soy or wheat-bran intervention was unable to alter excretion from baseline (Lampe et al, 2001) . Probiotic consumption did not significantly reduce plasma reproductive hormones, although the bacteria provided were similar in dose and bacterial species to those previously shown to significantly lower fecal b-glucuronidase activity in humans (Goldin and Gorbach, 1984; Benno and Mitsuoka, 1992) . It is possible that the microflora were altered in our subjects, but b-glucuronidase was not changed dramatically enough to significantly reduce enterohepatic recycling of these hormones. A second possibility is that the strains we used were not able to decrease b-glucuronidase activity. Differences between strains of the same bacterial species have been shown regarding resistance to stomach and bile acids as well as other factors that may jeopardize probiotic survival through the gastrointestinal tract (Bezkorovainy, 2001) .
It is possible to also evaluate the relationships among baseline characteristics, dietary factors, and reproductive hormones, although these analyses are limited by the relatively small sample size and must be interpreted with caution. The inverse association between follicularphase E 2 and BMI is similar to previous reports from studies performed in massively obese women (Grenman et al, 1986) , despite the fact that women in our study were within a normal range of BMI (18-31 kg/m 2 ). Also consistent with previous reports (Key et al, 2001) , we found an inverse correlation between SHBG and BMI. The inverse relationship found between SHBG and BMI is likely explained by the effect of BMI increasing insulin levels with subsequent inhibition of liver production of SHBG (Plymate et al, 1988; Franks et al, 1991) . Although the inverse relationship between A and BMI in our cohort was only of borderline significance, it is consistent with other reports (Grenman et al, 1986) , and may be explained by the increased metabolic clearance rate in obesity (Kirschner et al, 1983) .
The inverse association between A and protein:carbohydrate ratio has not been reported previously. Adlercreutz et al (1989) have previously reported an inverse association between A and carbohydrate intake, while testosterone, but not A, concentrations have been inversely related to the protein-to-carbohydrate ratio in other studies (Anderson et al, 1987; Volek et al, 1997) . Our data showed a trend toward this direction but results did not reach statistical significance. The mechanism for this relationship is not known; however, it has been hypothesized that dietary protein may alter liver enzyme systems that control metabolism of steroids and consequently circulating concentrations (Anderson et al, 1987) .
The inverse correlation between DHEA-S and dietary fiber is not consistent with some previous reports in premenopausal (Dorgan et al, 1996) or postmenopausal (Adlercreutz et al, 1989) women, yet one study in premenopausal women found DHEA-S to be significantly lower when a low-fat, highcarbohydrate diet was consumed (Bhathena et al, 1989) . Most studies of diet and hormones have generally evaluated T, A, E 1 or E 2 and have not measured DHEA-S (Hämäläinen et al, 1983; Goldin and Gorbach, 1994) .
A strength of this study was the ethnic diversity of subjects who participated, though the actual number of subjects in each ethnic group was small. Out of the four Asian subjects, three were recent immigrants and only one had lived mainly in North America. Interestingly, all the three Asian-born subjects who had lived mainly in Asia were equol excretors. Compared with the typical 30-40% rate of equol excretors in western populations, Adlercreutz et al (1991) reported that 47% of Japanese men and women were equol excretors. A more recent study (Morton et al, 2002) of Japanese men and women found the prevalence of female excretors close to those found in Western populations, but the prevalence among males was 58%. These results suggest that the prevalence of equol excretion in Asia is higher than that in the West. Perhaps the microflora necessary to metabolize daidzein to equol is more predominant in individuals consuming a traditional Asian diet.
In conclusion, our study of healthy premenopausal women showed significant inverse correlations at baseline between E 2 and body mass index (BMI), SHBG and BMI, DHEA-S and dietary fiber, and between A and protein:carbohydrate ratio. A 2-month consumption of Lactobacillus acidophilus and Bifidobacterium longum did not significantly decrease plasma reproductive hormones from baseline, although trends were found toward decreased T and SHBG. We confirmed reports that equol excretors do not show a unique dietary pattern and found that probiotic consumption did not increase equol excretion. We did not confirm our previous finding of breast cancer-preventive hormone profiles in premenopausal equol excretors. Given that in our previous study, the women were consuming at least 10 mg isoflavones/day in soy protein isolate, these data suggest that a minimum quantity of isoflavones taken in soy protein may be required to alter endogenous hormones in equol excretors. Future research should determine the effects of very low doses of soy isoflavones on plasma hormones in equol excretors and nonexcretors, as well as the specific bacterial species and strains that may alter intestinal microflora and increase equol production.
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